Mylan CEO Eyes Acquisitions Valued at More than $4 Billion

Generic-drug maker Mylan is on the prowl for acquisitions to bolster its product line and expand geographically, and would consider deals valued at “well over” $4 billion, the company’s leader said Thursday.
The Wall Street Journal